Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
November 20, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 ...
November 17, 2024 10:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
November 05, 2024 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 31, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 21, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management...
October 19, 2024 08:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and...
October 16, 2024 16:35 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 11, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s...
October 09, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right